Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia

Seminars in Cancer Biology

Volumn 19, Issue 3, 2009, Pages 158-164

  Niller, Hans Helmut ^a   Wolf, Hans ^a   Minarovits, Janos ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

Author keywords

Epigenetic regulation; Epstein Barr virus; Gastric carcinoma; Latency; Nasopharyngeal carcinoma; Tumor suppressor gene

Indexed keywords

DNA METHYLTRANSFERASE; ISOTRETINOIN; LATENT MEMBRANE PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE;

B LYMPHOCYTE; BURKITT LYMPHOMA; CELL SPECIFICITY; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE SILENCING; GERMINAL CENTER; HODGKIN DISEASE; HOST CELL; HUMAN; LYMPHOBLASTOID CELL; MEMORY CELL; NASOPHARYNX CANCER; NONHUMAN; REVIEW; STOMACH CARCINOMA; TUMOR CELL; VIRUS GENE; VIRUS GENOME; VIRUS LATENCY;

B-LYMPHOCYTES; DNA METHYLATION; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENE SILENCING; HERPESVIRUS 4, HUMAN; HUMANS; PROMOTER REGIONS, GENETIC; VIRAL PROTEINS; VIRUS LATENCY;

EID: 63449133614     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.02.012     Document Type: Review

References (141)

1. Wolf H., zur Hausen H., and Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol 244 (1973) 245-247
2. Desgranges C., Wolf H., de The G., Shanmugaratnam K., Cammoun N., Ellouz R., et al. Nasopharyngeal carcinoma. X. Presence of Epstein-Barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int J Cancer 16 (1975) 7-15
3. Niller H.H., Wolf H., and Minarovits J. Epstein-Barr virus. In: Minarovits J., Gonczol E., and Valyi-Nagy T. (Eds). Latency strategies of herpesviruses (2007), Springer, New York 154-191
4. Niller H.H., Wolf H., and Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 41 (2008) 298-328
5. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204 (2007) 2899-2912
6. Esteller M. Epigenetics in cancer. N Engl J Med 358 (2008) 1148-1159
7. Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol 40 (2007) 142-150
8. Niller H.H., Salamon D., Banati F., Schwarzmann F., Wolf H., and Minarovits J. The LCR of EBV makes Burkitt's lymphoma endemic. Trends Microbiol 12 (2004) 495-499
9. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., et al. Identification of virus-encoded microRNAs. Science 304 (2004) 734-736
10. Cai X., Schafer A., Lu S., Bilello J.P., Desrosiers R.C., Edwards R., et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2 (2006) e23
11. Grundhoff A., Sullivan C.S., and Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12 (2006) 733-750
12. Minarovits J. Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 310 (2006) 61-80
13. Niller H.H., Salamon D., Ilg K., Koroknai A., Banati F., Schwarzmann F., et al. EBV-associated neoplasms: alternative pathogenetic pathways. Med Hypotheses 62 (2004) 387-391
14. Bellan C., Lazzi S., Hummel M., Palummo N., de Santi M., Amato T., et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 106 (2005) 1031-1036
15. Hummel M., Bentink S., Berger H., Klapper W., Wessendorf S., Barth T.F., et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354 (2006) 2419-2430
16. Lindstrom M.S., and Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12 (2002) 381-387
17. Rossi D., Capello D., Gloghini A., Franceschetti S., Paulli M., Bhatia K., et al. Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica 89 (2004) 154-164
18. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., and Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57 (1997) 837-841
19. Kawano S., Miller C.W., Gombart A.F., Bartram C.R., Matsuo Y., Asou H., et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94 (1999) 1113-1120
20. Katzenellenbogen R.A., Baylin S.B., and Herman J.G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93 (1999) 4347-4353
21. Doucet J.P., Hussain A., Al Rasheed M., Gaidano G., Gutierrez M.I., Magrath I., et al. Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma 45 (2004) 357-362
22. Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G., Magrath I., et al. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 59 (1999) 696-703
23. Hussain A., Doucet J.P., Gutierrez M., Ahmad M., Al Hussein K., Capello D., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins. Haematologica 88 (2003) 167-175
24. Garrison S.P., Jeffers J.R., Yang C., Nilsson J.A., Hall M.A., Rehg J.E., et al. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 28 (2008) 5391-5402
25. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109 (2007) 271-280
26. Murai M., Toyota M., Satoh A., Suzuki H., Akino K., Mita H., et al. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 92 (2005) 1165-1172
27. Sinclair A.J., Palmero I., Holder A., Peters G., and Farrell P.J. Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol 69 (1995) 1292-1295
28. Li Y., Nagai H., Ohno T., Yuge M., Hatano S., Ito E., et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 100 (2002) 2572-2577
29. Ying J., Srivastava G., Hsieh W.S., Gao Z., Murray P., Liao S.K., et al. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 11 (2005) 6442-6449
30. Syed N., Smith P., Sullivan A., Spender L.C., Dyer M., Karran L., et al. Transcriptional silencing of Polo-like Kinase 2 (Snk/Plk2) is a frequent event in B cell malignancies. Blood (2005)
31. Hussain A., Gutierrez M.I., Timson G., Siraj A.K., Deambrogi C., Al Rasheed M., et al. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation. Genes Chromosomes Cancer 41 (2004) 321-329
32. Ying J., Li H., Cui Y., Wong A.H., Langford C., and Tao Q. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia 20 (2006) 1173-1175
33. Ying J., Li H., Chen Y.W., Srivastava G., Gao Z., and Tao Q. WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood 110 (2007) 4130-4132
34. Ying J., Li H., Seng T.J., Langford C., Srivastava G., Tsao S.W., et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25 (2006) 1070-1080
35. Ying J., Gao Z., Li H., Srivastava G., Murray P.G., Goh H.K., et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol 136 (2007) 829-832
36. Ying J., Li H., Murray P., Gao Z., Chen Y.W., Wang Y., et al. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Epigenetics 2 (2007) 15-21
37. Mathas S., Janz M., Hummel F., Hummel M., Wollert-Wulf B., Lusatis S., et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 7 (2006) 207-215
38. Ushmorov A., Leithauser F., Ritz O., Barth T.F., Moller P., and Wirth T. ABF-1 is frequently silenced by promoter methylation in follicular lymphoma, diffuse large B-cell lymphoma and Burkitt's lymphoma. Leukemia 22 (2008) 1942-1944
39. Kuppers R., Rajewsky K., Zhao M., Simons G., Laumann R., Fischer R., et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 91 (1994) 10962-10966
40. Kanzler H., Kuppers R., Hansmann M.L., and Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184 (1996) 1495-1505
41. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. (2007), Lippincott Williams Wilkins, Philadelphia 2603-2654
42. Tsai C.N., Tsai C.L., Tse K.P., Chang H.Y., and Chang Y.S. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 99 (2002) 10084-10089
43. Tsai C.L., Li H.P., Lu Y.J., Hsueh C., Liang Y., Chen C.L., et al. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 66 (2006) 11668-11676
44. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 (1997) 2961-2969
45. Schwering I., Brauninger A., Klein U., Jungnickel B., Tinguely M., Diehl V., et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101 (2003) 1505-1512
46. Garcia J.F., Camacho F.I., Morente M., Fraga M., Montalban C., Alvaro T., et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101 (2003) 681-689
47. Garcia M.J., Martinez-Delgado B., Cebrian A., Martinez A., Benitez J., and Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. Am J Pathol 161 (2002) 1007-1013
48. Sanchez-Aguilera A., Delgado J., Camacho F.I., Sanchez-Beato M., Sanchez L., Montalban C., et al. Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 103 (2004) 2351-2357
49. Murray P.G., Qiu G.H., Fu L., Waites E.R., Srivastava G., Heys D., et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 23 (2004) 1326-1331
50. Kato N., Fujimoto H., Yoda A., Oishi I., Matsumura N., Kondo T., et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. Cell Death Differ 11 Suppl. 2 (2004) S153-S161
51. Shiramizu B., and Mick P. Epigenetic changes in the DAP-kinase CpG island in pediatric lymphoma. Med Pediatr Oncol 41 (2003) 527-531
52. Stein H., Marafioti T., Foss H.D., Laumen H., Hummel M., Anagnostopoulos I., et al. Down-regulation of BOB.1/OBF. 1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97 (2001) 496-501
53. Torlakovic E., Tierens A., Dang H.D., and Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 159 (2001) 1807-1814
54. Ushmorov A., Ritz O., Hummel M., Leithauser F., Moller P., Stein H., et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 104 (2004) 3326-3334
55. Doerr J.R., Malone C.S., Fike F.M., Gordon M.S., Soghomonian S.V., Thomas R.K., et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J Mol Biol 350 (2005) 631-640
56. Ushmorov A., Leithauser F., Sakk O., Weinhausel A., Popov S.W., Moller P., et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 107 (2006) 2493-2500
57. Ehlers A., Oker E., Bentink S., Lenze D., Stein H., and Hummel M. Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia 22 (2008) 835-841
58. Zeng Y. EB virus and nasopharyngeal carcinoma. In: Zeng Y., and Ou B. (Eds). Etiology and pathogenesis of nasopharyngeal carcinoma (1987), The People's Medical Publishing House, Beijing 18
59. Feng B.J., Huang W., Shugart Y.Y., Lee M.K., Zhang F., Xia J.C., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 31 (2002) 395-399
60. Xiong W., Zeng Z.Y., Xia J.H., Xia K., Shen S.R., Li X.L., et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 64 (2004) 1972-1974
61. Lo K.W., To K.F., and Huang D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 5 (2004) 423-428
62. Raab-Traub N., and Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47 (1986) 883-889
63. Li X., Wang E., Zhao Y.D., Ren J.Q., Jin P., Yao K.T., et al. Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results. J Transl Med 4 (2006) 4
64. Tao Q., and Chan A.T. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9 (2007) 1-24
65. Chan A.S., To K.F., Lo K.W., Mak K.F., Pak W., Chiu B., et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 60 (2000) 5365-5370
66. Chan A.S., To K.F., Lo K.W., Ding M., Li X., Johnson P., et al. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int J Cancer 102 (2002) 300-303
67. Pathmanathan R., Prasad U., Sadler R., Flynn K., and Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333 (1995) 693-698
68. Cheung S.T., Huang D.P., Hui A.B., Lo K.W., Ko C.W., Tsang Y.S., et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83 (1999) 121-126
69. Fung L.F., Lo A.K., Yuen P.W., Liu Y., Wang X.H., and Tsao S.W. Differential gene expression in nasopharyngeal carcinoma cells. Life Sci 67 (2000) 923-936
70. Xie L., Xu L., He Z., Zhou W., Wang L., Zhang L., et al. Identification of differentially expressed genes in nasopharyngeal carcinoma by means of the Atlas human cancer cDNA expression array. J Cancer Res Clin Oncol 126 (2000) 400-406
71. Sriuranpong V., Mutirangura A., Gillespie J.W., Patel V., Amornphimoltham P., Molinolo A.A., et al. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin Cancer Res 10 (2004) 4944-4958
72. Yang X.Y., Ren C.P., Wang L., Li H., Jiang C.J., Zhang H.B., et al. Identification of differentially expressed genes in metastatic and non-metastatic nasopharyngeal carcinoma cells by suppression subtractive hybridization. Cell Oncol 27 (2005) 215-223
73. Zhang S.Q., Peng H., Song L.Y., Li X.M., Jiang H.Y., Yao K.T., et al. Detection of KIAA1173 gene expression in nasopharyngeal carcinoma tissues and cell lines on tissue microarray. Ai Zheng 24 (2005) 1322-1326
74. Zeng Z.Y., Zhou Y.H., Zhang W.L., Xiong W., Fan S.Q., Li X.L., et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol 38 (2007) 120-133
75. Kwong J., Lo K.W., To K.F., Teo P.M., Johnson P.J., and Huang D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8 (2002) 131-137
76. Tsao S.W., Liu Y., Wang X., Yuen P.W., Leung S.Y., Yuen S.T., et al. The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. Eur J Cancer 39 (2003) 524-531
77. Zheng Z., Pan J., Chu B., Wong Y.C., Cheung A.L., and Tsao S.W. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol 30 (1999) 458-466
78. Krishna S.M., Kattoor J., and Balaram P. Down regulation of adhesion protein E-cadherin in Epstein-Barr virus infected nasopharyngeal carcinomas. Cancer Biomark 1 (2005) 271-277
79. Niemhom S., Kitazawa S., Kitazawa R., Maeda S., and Leopairat J. Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detect Prev 32 (2008) 127-134
80. Lo A.K., To K.F., Lo K.W., Lung R.W., Hui J.W., Liao G., et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A 104 (2007) 16164-16169
81. Peng D., Ren C.P., Yi H.M., Zhou L., Yang X.Y., Li H., et al. Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai) 38 (2006) 349-355
82. Ayadi W., Karray-Hakim H., Khabir A., Feki L., Charfi S., Boudawara T., et al. Aberrant methylation of p16, DLEC1.BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res 28 (2008) 2161-2167
83. Liu H., Zhang L., Niu Z., Zhou M., Peng C., Li X., et al. Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. BMC Cancer 8 (2008) 253
84. Cui Y., Ying Y., van Hasselt A., Ng K.M., Yu J., Zhang Q., et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE 3 (2008) e2990
85. Jin H., Wang X., Ying J., Wong A.H., Li H., Lee K.Y., et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 26 (2007) 7490-7498
86. Lung H.L., Lo P.H., Xie D., Apte S.S., Cheung A.K., Cheng Y., et al. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int J Cancer 123 (2008) 401-408
87. Yi H.M., Li H., Peng D., Zhang H.J., Wang L., Zhao M., et al. Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res 16 (2006) 261-272
88. Zhou Y., Zeng Z., Zhang W., Xiong W., Wu M., Tan Y., et al. Lactotransferrin: a candidate tumor suppressor-Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 123 (2008) 2065-2072
89. Lee K.Y., Geng H., Ng K.M., Yu J., van Hasselt A., Cao Y., et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 27 (2008) 5267-5276
90. Lo K.W., Tsang Y.S., Kwong J., To K.F., Teo P.M., and Huang D.P. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 98 (2002) 651-655
91. Zhou L., Feng X., Shan W., Zhou W., Liu W., Wang L., et al. Epigenetic and genetic alterations of the EDNRB gene in nasopharyngeal carcinoma. Oncology 72 (2007) 357-363
92. Jin H., Wang X., Ying J., Wong A.H., Cui Y., Srivastava G., et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci U S A 104 (2007) 12353-12358
93. Shao L., Cui Y., Li H., Liu Y., Zhao H., Wang Y., et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res 13 (2007) 5756-5762
94. Zhou L., Jiang W., Ren C., Yin Z., Feng X., Liu W., et al. Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia 7 (2005) 809-815
95. Lam P.K., To E.W., Chan E.S., Liew C.T., Lung I.W., and King W.K. In vitro inhibition of head and neck cancer-cell growth by human recombinant interferon-alpha and 13-cis retinoic acid. Br J Biomed Sci 58 (2001) 226-229
96. Kwong J., Lo K.W., Chow L.S., To K.F., Choy K.W., Chan F.L., et al. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 7 (2005) 67-74
97. Kwong J., Lo K.W., Chow L.S., Chan F.L., To K.F., and Huang D.P. Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int J Cancer 113 (2005) 386-392
98. Seo S.Y., Kim E.O., and Jang K.L. Epstein-Barr virus latent membrane protein 1 suppresses the growth-inhibitory effect of retinoic acid by inhibiting retinoic acid receptor-beta2 expression via DNA methylation. Cancer Lett 270 (2008) 66-76
99. Lin Y.C., You L., Xu Z., He B., Mikami I., Thung E., et al. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun 341 (2006) 635-640
100. Chan S.L., Cui Y., van Hasselt A., Li H., Srivastava G., Jin H., et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest 87 (2007) 644-650
101. Choy E.Y., Siu K.L., Kok K.H., Lung R.W., Tsang C.M., To K.F., et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 205 (2008) 2551-2560
102. Imai S., Koizumi S., Sugiura M., Tokunaga M., Uemura Y., Yamamoto N., et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 91 (1994) 9131-9135
103. Uozaki H., and Fukayama M. Epstein-Barr virus and gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 1 (2008) 198-216
104. van Beek J., zur H.A., Klein K.E., van de Velde C.J., Middeldorp J.M., van den Brule A.J., et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22 (2004) 664-670
105. Chen X., Leung S.Y., Yuen S.T., Chu K.M., Ji J., Li R., et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 14 (2003) 3208-3215
106. Chong J.M., Sakuma K., Sudo M., Osawa T., Ohara E., Uozaki H., et al. Interleukin-1beta expression in human gastric carcinoma with Epstein-Barr virus infection. J Virol 76 (2002) 6825-6831
107. Lee H.S., Chang M.S., Yang H.K., Lee B.L., and Kim W.H. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res 10 (2004) 1698-1705
108. Fukayama M., Hino R., and Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci 99 (2008) 1726-1733
109. Hino R., Uozaki H., Inoue Y., Shintani Y., Ushiku T., Sakatani T., et al. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res 68 (2008) 1427-1435
110. Fukuda M., and Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol 81 (2007) 9299-9306
111. Wang Q., Tsao S.W., Ooka T., Nicholls J.M., Cheung H.W., Fu S., et al. Anti-apoptotic role of BARF1 in gastric cancer cells. Cancer Lett (2005)
112. Wiech T., Nikolopoulos E., Lassman S., Heidt T., Schopflin A., Sarbia M., et al. Cyclin D1 expression is induced by viral BARF1 and is overexpressed in EBV-associated gastric cancer. Virchows Arch 452 (2008) 621-627
113. Toyota M., Ahuja N., Suzuki H., Itoh F., Ohe-Toyota M., Imai K., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59 (1999) 5438-5442
114. Maekita T., Nakazawa K., Mihara M., Nakajima T., Yanaoka K., Iguchi M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12 (2006) 989-995
115. Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 15 (2006) 2317-2321
116. Lee J.H., Park S.J., Abraham S.C., Seo J.S., Nam J.H., Choi C., et al. Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23 (2004) 4646-4654
117. Kang G.H., Lee S., Kim W.H., Lee H.W., Kim J.C., Rhyu M.G., et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 160 (2002) 787-794
118. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., and Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97 (2006) 64-71
119. Akino K., Toyota M., Suzuki H., Imai T., Maruyama R., Kusano M., et al. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci 98 (2007) 88-95
120. Kang G.H., Lee S., Kim J.S., and Jung H.Y. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 83 (2003) 635-641
121. Kim T.Y., Jong H.S., Jung Y., Kim T.Y., Kang G.H., and Bang Y.J. DNA hypermethylation in gastric cancer. Aliment Pharmacol Ther 20 Suppl. 1 (2004) 131-142
122. Kawamura Y.I., Toyota M., Kawashima R., Hagiwara T., Suzuki H., Imai K., et al. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 135 (2008) 142-151
123. Kim T.Y., Jong H.S., Song S.H., Dimtchev A., Jeong S.J., Lee J.W., et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 22 (2003) 3943-3951
124. Maruyama R., Akino K., Toyota M., Suzuki H., Imai T., Ohe-Toyota M., et al. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29 (2008) 1312-1318
125. Kusano M., Toyota M., Suzuki H., Akino K., Aoki F., Fujita M., et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 106 (2006) 1467-1479
126. Chong J.M., Sakuma K., Sudo M., Ushiku T., Uozaki H., Shibahara J., et al. Global and non-random CpG-island methylation in gastric carcinoma associated with Epstein-Barr virus. Cancer Sci 94 (2003) 76-80
127. Chang M.S., Uozaki H., Chong J.M., Ushiku T., Sakuma K., Ishikawa S., et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 12 (2006) 2995-3002
128. Enomoto S., Maekita T., Tsukamoto T., Nakajima T., Nakazawa K., Tatematsu M., et al. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci 98 (2007) 1853-1861
129. Etoh T., Kanai Y., Ushijima S., Nakagawa T., Nakanishi Y., Sasako M., et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 164 (2004) 689-699
130. Kim J., Lee H.S., Bae S.I., Lee Y.M., and Kim W.H. Silencing and CpG island methylation of GSTP1 is rare in ordinary gastric carcinomas but common in Epstein-Barr virus-associated gastric carcinomas. Anticancer Res 25 (2005) 4013-4019
131. Chang M.S., Lee H.S., Kim H.S., Kim S.H., Choi S.I., Lee B.L., et al. Epstein-Barr virus and microsatellite instability in gastric carcinogenesis. J Pathol 199 (2003) 447-452
132. Vo Q.N., Geradts J., Gulley M.L., Boudreau D.A., Bravo J.C., and Schneider B.G. Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. J Clin Pathol 55 (2002) 669-675
133. Osawa T., Chong J.M., Sudo M., Sakuma K., Uozaki H., Shibahara J., et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn J Cancer Res 93 (2002) 1195-1200
134. Sakuma K., Chong J.M., Sudo M., Ushiku T., Inoue Y., Shibahara J., et al. High-density methylation of p14ARF and p16INK4A in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 112 (2004) 273-278
135. Ushiku T., Chong J.M., Uozaki H., Hino R., Chang M.S., Sudo M., et al. p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 120 (2007) 60-66
136. Kang G.H., Lee S., Cho N.Y., Gandamihardja T., Long T.I., Weisenberger D.J., et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88 (2008) 161-170
137. zur Hausen A., van Rees B.P., van Beek J., Craanen M.E., Bloemena E., Offerhaus G.J., et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 57 (2004) 487-491
138. Au W.Y., Pang A., Chan E.C., Chu K.M., Shek T.W., and Kwong Y.L. Epstein-Barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology 129 (2005) 2058-2063
139. Akiba S., Koriyama C., Herrera-Goepfert R., and Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci 99 (2008) 195-201
140. Chuang J.C., and Jones P.A. Epigenetics and microRNAs. Pediatr Res 61 (2007) 24R-29R
141. Matarazzo M.R., De Bonis M.L., Strazzullo M., Cerase A., Ferraro M., Vastarelli P., et al. Multiple binding of methyl-CpG and polycomb proteins in long-term gene silencing events. J Cell Physiol 210 (2007) 711-719